National Research Corporation Stock Price and Value Analysis

National Research Corporation (NASDAQ:NRC) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold National Research Corporation to reach your target.

Target type

NRC Free Cash Flow Trend

Free Cash Flow trendline for NRC
Free Cash Flow trendline for National Research Corporation
CSV

Based on historical returns, we believe that National Research Corporation can grow its free cash at a rate of about 25%. That's positive!

AdvantagesDisadvantages
  • This company has fluctuating growth.
  • This company is making money at a great rate!
  • This company has a high dividend yield.
  • This stock looks overpriced.
  • This company is less known than others.

Inside the NRC Numbers

NRC Price
(National Research Corporation stock price per share)
$25.16
[?] NRC Fair Price
(based on intrinsic value)
$0.66
[?] NRC Safety Price (based on a variable margin of safety) $0.40
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 359% higher than other Healthcare stocks
[?] PE Ratio versus Industry 0% lower than other Diagnostics & Research stocks
[?] Free Cash Flow Jitter 30%
[?] Dividend Yield 2.56% (tax impact)
Shares Shorted 686,809

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 686,809 shares shorted. With 11,059,817 shares available for purchase and an average trading volume over the past 10 trading days of 100,290, it would take at least 6.8 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2009 70487 10.8
2010 70487 12.4
2011 70487 16.1
2012 70487 16.7
2013 70487 17
2014 70487 23.9
2015 70487 19.3
2016 70487 24.1
2017 70487 24.9
2018 70487 35.9
2019 70487 36.5
2020 70487 36
2021 70487 41.4
2022 70487 30.3
2023 70487 30.2
2024 70487 24.5
2025 70487 15

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 10 fiscal years from 2009 to 2018 with positive net income, operating cash flow totaled $228 million against net income of $171 million, or 1.33 times.

In 2018, operating cash flow was 1.33 times net income, compared with 1.48 times for the earliest three years (2009 to 2011).

In 2018, capital expenditures were $6 million, 15.0% of operating cash flow of $39.8 million, which leaves an estimated $33.9 million after capex. Across the 10 years with reported capex, it averaged 13.9% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2009 8.5 13.7 2.9 1.61
2010 11.6 14.6 1.5 1.26
2011 11.6 18.5 2.8 1.60
2012 15.1 19.1 2.3 1.27
2013 15.5 19.3 2.2 1.25
2014 18.2 26.2 2.5 1.44
2015 17.6 21.9 2.9 1.24
2016 20.5 26.8 4 1.31
2017 22.9 28.1 4.6 1.22
2018 30 39.8 6 1.33

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2016 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $299 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In the 10 of those years with dividend payment facts, dividends paid totaled $193 million, 64.6% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 8 of those 10 years.

In 5 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $102 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, dividends and cash spent repurchasing shares together were $31.2 million, 207.8% of estimated free cash flow of $15 million. That was more than the estimated free cash flow of the year.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2016 24.1 28.6 n/a 28.6 118.7%
2017 24.9 16.9 n/a 16.9 67.9%
2018 35.9 16.9 n/a 16.9 47.0%
2019 36.5 31.3 n/a 31.3 85.8%
2020 36 10.5 n/a 10.5 29.2%
2021 41.4 9.2 4.1 13.3 32.1%
2022 30.3 21 27.6 48.6 160.5%
2023 30.2 36.4 19.1 55.5 183.9%
2024 24.5 11.5 30.9 42.4 173.0%
2025 15 11 20.2 31.2 207.8%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $57.7 million in 2009 and $137 million in 2025, a compound annual growth rate of 5.6% over 16 years.

Revenue fell 4.0% from 2024 to 2025.

Our estimated free cash flow was $15 million in 2025, 10.9% of revenue. In 2009 the estimated margin was 18.6%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2009 57.7 10.8 18.6%
2010 63.4 12.4 19.5%
2011 75.8 16.1 21.2%
2012 86.4 16.7 19.4%
2013 92.6 17 18.3%
2014 98.8 23.9 24.2%
2015 102 19.3 18.9%
2016 109 24.1 22.0%
2017 118 24.9 21.1%
2018 120 35.9 30.0%
2019 128 36.5 28.5%
2020 133 36 27.0%
2021 148 41.4 28.0%
2022 152 30.3 20.0%
2023 149 30.2 20.3%
2024 143 24.5 17.1%
2025 137 15 10.9%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $4.1 million against total liabilities of $121 million, or 3.4% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 89.6% of total assets in 2025, compared with 49.3% in 2010, an increase of 40.4 percentage points.

Stockholders equity was $14 million in 2025, compared with $48.6 million in 2010, a fall of 71.2%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 15.9% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2010 95.8 3.5 47.2 48.6
2011 101 8.1 45.1 55.6
2012 100 8.3 43.3 56.7
2013 111 22.1 39.3 71.8
2014 130 40 41.8 87.7
2015 128 42.1 53.8 74.2
2016 121 33 37.8 82.8
2017 127 34.7 37.3 90
2018 108 13 88.9 19.1
2019 111 13.5 77.8 32.9
2020 133 34.7 69.1 64.3
2021 158 54.4 72.2 85.3
2022 130 25 58.4 72
2023 122 6.7 73.5 49
2024 133 4.2 101 31.3
2025 135 4.1 121 14

Price Versus Our Estimated Value

Free cash flow was positive in all 17 fiscal years we have for National Research Corporation under its current SEC filer.

Average free cash flow over the last three years of data was $23.2 million, and across the first three years it was $13.1 million; over the period it rose sharply.

Free cash flow is uneven from year to year, with a variability measure of 30%.

National Research Corporation is priced at $25.16, above our fair value estimate of $0.66 and its safe value of $0.40.

Its dividend yield is 2.56%.

Our value investing guide explains how to test these numbers against the filings themselves.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 359% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is in line with the average for stocks in the Diagnostics & Research industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Diagnostics & Research industry, the ones closest in market capitalization to National Research Corporation, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
National Research Corporation (NRC) 534 93.2 2.6% - 3712% above
RadNet (RDNT) 5,491 - - 1.4% 42% below
Lantheus Holdings (LNTH) 6,677 25.4 - - 513% above
Charles River Laboratories International (CRL) 15,061 341.7 - 2.1% 70% above
Medpace Holdings (MEDP) 17,078 33.9 - - 3621% above
Incyte Corporation (INCY) 23,364 58.5 - 0.6% 166% above
Quest Diagnostics Incorporated (DGX) 28,416 25.7 1.3% 3.0% 25% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 70487.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: NRC annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in NRC

Does National Research Corporation have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: NRC

This example shows how we apply the Trendshare checklist to NRC: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 25.16
    • Market cap: $534M
    • EPS: 0.27
  2. Step 2 — Valuation checks

    • P/E: 93.185
    • FCF yield: —
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.